Your session is about to expire
← Back to Search
CAR T-cell Therapy
CTX130 for Kidney Cancer
Phase 1
Waitlist Available
Research Sponsored by CRISPR Therapeutics AG
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
Age ≥18 years and body weight ≥42 kg
Karnofsky performance status (KPS) ≥80%
Must not have
Prior solid organ transplantation or bone marrow transplant
Prior treatment with any CAR T cells or any other modified T or natural killer (NK) cells
Timeline
Screening 3 weeks
Treatment Varies
Follow Up from ctx130 infusion up to 60 months post-infusion]
Awards & highlights
No Placebo-Only Group
Summary
This trial is testing a new cancer drug to see if it is safe and effective in treating kidney cancer that has come back or does not respond to treatment.
Who is the study for?
This trial is for adults over 18 with a weight of at least 42 kg who have kidney cancer that's gotten worse or hasn't responded to treatment. They must be able to perform daily activities well (KPS ≥80%) and agree to use contraception for a year post-treatment. People can't join if they've had organ transplants, previous CAR T cell therapy, certain severe health conditions, are pregnant/breastfeeding, have untreated HIV/hepatitis infections, or other active cancers.
What is being tested?
The study is testing CTX130's safety and effectiveness in treating renal cell carcinoma that has relapsed or doesn't respond anymore. It's an early-phase trial where all participants receive the same experimental therapy without any comparison group.
What are the potential side effects?
While specific side effects of CTX130 aren't listed here, similar therapies often cause immune reactions, fatigue, possible organ inflammation due to immune response, and increased risk of infection.
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowSelect...
I am 18 years or older and weigh at least 42 kg.
Select...
I am mostly able to carry out normal activities without assistance.
Select...
My kidney cancer cannot be surgically removed and has not responded to standard treatments.
Exclusion Criteria
You may be eligible for the trial if you check “No” for criteria below:Select...
I have had a solid organ or bone marrow transplant.
Select...
I have not had treatments involving modified immune cells.
Select...
I have an immune system disorder or autoimmune disease treated with steroids or other immune-suppressing drugs.
Select...
I have never been treated with drugs targeting CD70.
Select...
I do not have active HIV, hepatitis B, or hepatitis C.
Timeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ from ctx130 infusion up to 60 months post-infusion]
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~from ctx130 infusion up to 60 months post-infusion]
Treatment Details
Study Objectives
Study objectives can provide a clearer picture of what you can expect from a treatment.Primary study objectives
Part A (dose escalation): Incidence of adverse events
Part B (cohort expansion): Objective response rate
Awards & Highlights
No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.
Trial Design
1Treatment groups
Experimental Treatment
Group I: CTX130Experimental Treatment1 Intervention
Administered by IV infusion following lymphodepleting chemotherapy.
Find a Location
Who is running the clinical trial?
CRISPR Therapeutics AGLead Sponsor
8 Previous Clinical Trials
785 Total Patients Enrolled
Matthias Will, MDStudy DirectorCRISPR Therapeutics
3 Previous Clinical Trials
124 Total Patients Enrolled
Anjali Sharma, MDStudy DirectorCRISPR Therapeutics
1 Previous Clinical Trials
45 Total Patients Enrolled
Media Library
Eligibility Criteria:
This trial includes the following eligibility criteria:- I have had a solid organ or bone marrow transplant.I had cancer before but it's been treated, hasn't needed more treatment for over a year, and isn't likely to spread.I am 18 years or older and weigh at least 42 kg.I have not had treatments involving modified immune cells.I have a history of specific brain, heart, or lung conditions.I agree to use birth control from enrollment through 12 months after treatment.I am mostly able to carry out normal activities without assistance.My kidney cancer cannot be surgically removed and has not responded to standard treatments.I have an immune system disorder or autoimmune disease treated with steroids or other immune-suppressing drugs.I have never been treated with drugs targeting CD70.I do not have active HIV, hepatitis B, or hepatitis C.My kidney, liver, heart, and lung functions are all good.
Research Study Groups:
This trial has the following groups:- Group 1: CTX130
Awards:
This trial has 1 awards, including:- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
Timeline:
This trial has the following timeline:- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Other Trials to Consider
Popular Categories
Share this study with friends
Copy Link
Messenger